Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 6 of 6 for “"chAd3"”.

  1. Examining Anti-viral Immune Responses in Vaccination and Infection

    … vaccine trial using chimpanzee adenovirus 3 (ChAd3) and modified vaccinia Ankara (MVA) was not effective in preventing chronic hepatitis C virus (HCV) and only elicited anti-HCV T cell responses in 78% of vaccinees, compared to 100% of vaccinees in a previous trial of healthy participants. We …

    jhu Repository record for Examining Anti-viral Immune Responses in Vaccination and Infection (opens in a new tab)

  2. Comparing the efficacy and safety of potential clinical vaccines for the Ebola virus

    … be developed into a future vaccine for Ebola: chAd3, rVSV, and rAd5. Each of the vaccines has been the focus of several studies on both animals and humans, which have provided information and understanding of the vaccines’ characteristics in terms of reactogenicity and immunogenicity. All of …

    bu Repository record for Comparing the efficacy and safety of potential clinical vaccines for the Ebola virus (opens in a new tab)

  3. Characterising immune responses to viral vectored vaccines against influenza and hepatitis C

    … to hepatitis C virus, I used the vaccines ChAd3-NSmut and MVA-NSmut in a prime-boost regimen. While the combination was highly immunogenic in healthy young adults, MVA-NSmut alone was unable to prime immune responses. The magnitude of T cell responses to the vaccine immunogen was correlated …

    oxford Repository record for Characterising immune responses to viral vectored vaccines against influenza and hepatitis C (opens in a new tab)

  4. Genetic and molecular technologies to optimise novel vaccines for Hepatitis C virus infection

    … vaccine regimen of a simian adenoviral vector (ChAd3), boosted with a modified vaccinia Ankara (MVA) encoding the non-structural (NS) proteins of HCV. This regimen elicits an unprecedented magnitude of HCV-specific CD8+ and CD4+ T-cells; which are broadly targeted, durable, and highly …

    oxford Repository record for Genetic and molecular technologies to optimise novel vaccines for Hepatitis C virus infection (opens in a new tab)

  5. Novel adenoviral vectored vaccines and the implications of viral diversity in therapeutic strategies against Hepatitis C Virus infection

    … the safety and immunogenicity of these vaccines (ChAd3–NSmut and Ad6-NSmut), for the first time in HCV infected patients. This work also explores whether vaccine-induced T cell responses target <em>in vivo</em> circulating HCV antigens and common naturally occurring epitope variants.</p> …

    oxford Repository record for Novel adenoviral vectored vaccines and the implications of viral diversity in therapeutic strategies against Hepatitis C Virus infection (opens in a new tab)

  6. Novel viral vector vaccines for tropical infections

    … of the viral vector Ebolavirus vaccine, ChAd3-EBO Z either given alone or in a heterologous prime-boost sequence with MVA-BN® Filo, for which this study is also a first in man evaluation.</p>

    oxford Repository record for Novel viral vector vaccines for tropical infections (opens in a new tab)